Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126872371 | 12687237 | 1 | I | 20160822 | 20160826 | 20160826 | EXP | MX-ROCHE-1817700 | ROCHE | NOLASCO-MEDINA D, REYNOSO-NOVERON N, MOHAR-BETANCOURT A, AVILES-SALAS A, GARCIA-PEREZ O AND CANDELARIA M. COMPARISON OF THREE CHEMOTHERAPY REGIMENS IN ELDERLY PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA: EXPERIENCE AT A SINGLE NATIONAL REFERENCE CENTER IN MEXICO. BIOMED RESEARCH INTERNATIONAL 2016;:1-11. | 0.00 | E | Y | 0.00000 | 20160826 | OT | MX | MX |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126872371 | 12687237 | 1 | PS | Rituximab | RITUXIMAB | 1 | Intravenous (not otherwise specified) | U | 103705 | 375 | MG/M**2 | SOLUTION FOR INFUSION | |||||||
| 126872371 | 12687237 | 2 | SS | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | Unknown | U | 0 | 750 | MG/M**2 | ||||||||
| 126872371 | 12687237 | 3 | SS | DOXORUBICIN | DOXORUBICIN | 1 | Unknown | 50 MG/M2 IN RCHOP GROUP AND 25 MG/M2 IN RCHOP GROUP. | U | 0 | |||||||||
| 126872371 | 12687237 | 4 | SS | VINCRISTINE | VINCRISTINE | 1 | Unknown | MAXIMUM DOSE 2 MG | U | 0 | 1.4 | MG/M**2 | |||||||
| 126872371 | 12687237 | 5 | SS | PREDNISONE. | PREDNISONE | 1 | Unknown | 100 MG/DAY/5 DAYS EVERY 21 DAY CYCLE. | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126872371 | 12687237 | 1 | Diffuse large B-cell lymphoma |
| 126872371 | 12687237 | 2 | Diffuse large B-cell lymphoma |
| 126872371 | 12687237 | 3 | Diffuse large B-cell lymphoma |
| 126872371 | 12687237 | 4 | Diffuse large B-cell lymphoma |
| 126872371 | 12687237 | 5 | Diffuse large B-cell lymphoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126872371 | 12687237 | OT |
| 126872371 | 12687237 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126872371 | 12687237 | Bone marrow failure | |
| 126872371 | 12687237 | Cardiovascular disorder | |
| 126872371 | 12687237 | Febrile neutropenia | |
| 126872371 | 12687237 | Gastrointestinal disorder | |
| 126872371 | 12687237 | Infection | |
| 126872371 | 12687237 | Lung disorder | |
| 126872371 | 12687237 | Neoplasm | |
| 126872371 | 12687237 | Neuropathy peripheral | |
| 126872371 | 12687237 | Pain | |
| 126872371 | 12687237 | Renal disorder | |
| 126872371 | 12687237 | Thrombosis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |